Clinical Trials
6 trialsNCT07598955 2026-05-20
SELECT-NK-THYM
Beijing Biotech
Phase 1/2 Recruiting
NCT02743611 2023-10-05
Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT02065869 2023-09-29
Safety Study of Gene Modified Donor T-cells Following TCRαβ+ Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT03733249 2023-09-26
Long Term Follow-up Study for Patients Enrolled on the BP-004 Clinical Study
Bellicum Pharmaceuticals
Phase 1/2 Terminated
NCT01744223 2022-07-12
Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Active not recruiting
NCT03301168 2022-07-12
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
Bellicum Pharmaceuticals
Phase 1/2 Active not recruiting